To leverage all available biomedical research resources including technical expertise, hardware, and research mentors for the long-term goal of enhanced productivity and competitiveness, Xavier's RCMI will strive to build and expand strong, productive collaborations and partnerships both intra-institutionally and inter-institutionally. We have identified and assessed resources available to Xavier's research community and will focus on the research resources in collaborating institutions and the research strengths of Xavier's RCMI program, as well as taking advantage of the RCMI Translational Research Network (RTRN) for enhancing collaborative research among RCMI institutions. We propose the three specific aims in building extensive collaborations and partnerships:
Aim 1. Expand and enhance intra-institutional collaborations and partnerships among Xavier researchers by offering state-of-the-art core facilities and technical expertise that support and promote interdisciplinary research activities;
Aim 2. Strengthen collaborations and partnerships with RCMI institutions by effectively utilizing RTRN resources and the eagle-i database;
and Aim 3. Strengthen collaborations with Xavier's strategic partners at the Louisiana Cancer Research Consortium and the Louisiana Biomedical Research Network and develop new collaborations with the Louisiana Clinical and Translational Sciences Center. Through effective collaborations, Xavier's RCMI program will benefit from additional professional development resources such as mentors, increase funding opportunities such as multi-PI grant applications, and enhance research capabilities and competitiveness by having access to state-of-the-art technologies and instrumentation.

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Research Centers in Minority Institutions Award (G12)
Project #
2G12MD007595-06
Application #
8845383
Study Section
Special Emphasis Panel (ZMD1-MLS (01))
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$1,193,273
Indirect Cost
$272,747
Name
Xavier University of Louisiana
Department
Type
DUNS #
020857876
City
New Orleans
State
LA
Country
United States
Zip Code
70125
Zhang, Q; Liu, S; Parajuli, K R et al. (2017) Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene 36:687-699
Drennen, Callie; Gorse, Erin; Stratford Jr, Robert E (2017) Cellular Pharmacokinetic Model-Based Analysis of Genistein, Glyceollin, and MK-571 Effects on 5 (and 6)-Carboxy-2',7'-Dichloroflourescein Disposition in Caco-2 Cells. J Pharm Sci :
Liu, Yao-Zhong; Zhang, Lei; Roy-Engel, Astrid M et al. (2017) Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells. Gene 602:16-23
Rivera, Mariela; Ramos, Yanilda; Rodríguez-Valentín, Madeline et al. (2017) Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells. PLoS One 12:e0179587
Komati, Rajesh; Spadoni, Dominick; Zheng, Shilong et al. (2017) Ligands of Therapeutic Utility for the Liver X Receptors. Molecules 22:
Phambu, Nsoki; Almarwani, Bashiyar; Garcia, Arlette M et al. (2017) Chain length effect on the structure and stability of antimicrobial peptides of the (RW)n series. Biophys Chem 227:8-13
Joshi, Jugal Bharat; Patel, Divya; Morton, Derrick J et al. (2017) Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52. Mol Oncol 11:337-357
Zhang, Xiaojie; Guo, Shanchun; Chen, Chengsheng et al. (2017) Asymmetric 1,5-diarylpenta-1,4-dien-3-ones: Antiproliferative activity in prostate epithelial cell models and pharmacokinetic studies. Eur J Med Chem 137:263-279
Wang, Rubing; Zhang, Xiaojie; Chen, Chengsheng et al. (2017) Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models. Eur J Med Chem 133:208-226
Zhang, Wensheng; Edwards, Andrea; Flemington, Erik K et al. (2017) Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers. Cancer Inform 16:1176935117691267

Showing the most recent 10 out of 191 publications